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Abstract.  Recent studies using solid-phase-binding as- 
says and electron microscopy suggested the presence 
of a heparin-binding  domain between the inner globule 
of a lateral short arm and the cross region of laminin. 
Using the information from the amino acid sequence 
of the B1 chain of laminin,  several peptides were syn- 
thesized from areas with a low hydropathy index and a 
high density of lysines and/or arginines.  One of these, 
peptide F-9 (RYVVLPRPVCFEKGMNYTVR), which 
is derived from the inner globular domain of the 
lateral short arm,  demonstrated specific binding to 
heparin.  This was tested in direct solid-phase binding 
assays by coating the peptide either on nitrocellulose 
or on polystyrene and in indirect competition assays 
where the peptide was in solution and either laminin 
or heparin  was immobilized on a  solid support.  The 
binding of [3H]heparin to peptide F-9 was dramatically 
reduced when heparin but not other glycosamino- 
glycans other than heparin  (dextran sulfate, dermatan 
sulfate) were used in competition assays. Modification 
of the free amino groups of peptide F-9 by acetylation 
abolished its ability to inhibit the binding of [3H]hepa- 
fin to laminin on polystyrene surfaces. Peptide F-9 
promoted the adhesion of various cell lines (mela- 
noma,  fibrosarcoma, glioma,  pheochromocytoma) and 
of aortic endothelial cells. Furthermore,  when peptide 
F-9 was present in solution, it inhibited the adhesion 
of melanoma cells to laminin-coated  substrates.  These 
findings suggest that peptide F-9 defines a  novel 
heparin-binding  and cell adhesion-promoting  site on 
laminin. 
AMININ is  a large  (850 kD) basement  membrane glyco- 
protein  consisting  of three  polypeptide  chains  (BI, 
B2, A) held  together  by  disulfide  bonds (22,  39,  41). 
By rotary  shadowing and electron  microscopy,  laminin  has 
the shape of an asymmetric cross with three short arms, each 
with two globular domains near the ends, and one long arm 
with a large terminal  globular domain (6, 22, 39). 
Laminin  is involved in two general types of interactions. 
First, it binds to basement membrane macromolecules such 
as type IV collagen (4, 17), entactin/nidogen  (22, 28), hepa- 
ran sulfate protcoglycan (17), as well as to itself (42). These 
interactions  may be crucial in determining  the structure of 
basement membranes.  Second, it has the ability to interact 
with cell surface molecules, including a 67-kD receptor (19, 
21, 38), the CSAT antigen (11), and sulfated glycolipids (29). 
These interactions with cell surface molecules may influence 
the adhesion, growth, morphology, and migration (22-24) of 
various cell types. 
Laminin also has the ability to bind to hcparin  (30). Since 
macromolecules with heparin-like  side chains arc present in 
basement membranes (7, 13, 15, 18, 35) and on cell surfaces 
(8, 20, 35), this interaction may be very important.  Ott et al. 
(26) have localized a heparin-binding  domain on the globule 
at the distal  end of the long arm of laminin.  Their studies 
were performed with laminin  fragments derived after vari- 
ous enzymatic digestions.  It is possible, however, that other 
protease-sensitive,  heparin-binding  sites are present on the 
laminin molecule. We have recently localized two additional 
beparin-binding  domains on laminin using monoclonal anti- 
bodies (34).  One domain was localized to the middle of a 
short arm while the other domain was localized below the 
intersection  of the cross on the long arm of laminin. 
In this study,  we synthesized  various peptides from the 
published amino acid  sequence of the B1  chain  (31). We 
tested  these peptides for heparin-binding  properties using 
various solid-phase  assays. One of these peptides,  F-9, con- 
sistently  bound specifically  to heparin.  This  peptide was 
found to promote the adhesion of various cell lines in solid- 
phase assays and to compete with laminin  when added in 
solution. 
Materials and Methods 
Reagents 
Laminin  was  isolated  from  the  Engelbreth-Hoim-Swarm  (EHS)  tumor 
grown subcutaneously in Swiss Webster mice (Simonsen Laboratories, Inc., 
Gilroy, CA).  The mice we~ made lathyritic by adding 0.1% beta-amino 
proprionitrile to their water, using previously described techniques (4, 14). 
Heparin (porcine intestinal mucesa, grade I, 15 kD), dextran sulfate (8 kD), 
and dermatan sulfate  (porcine skin, type  13, 20 kD) were  all purchased from 
Sigma Chemical Co. (St. Louis,  MO). 
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Peptides were synthesized on a solid-phase support resin according to the 
technique of Barany and Merrifield (1). Deprotection and release of peptides 
was achieved by using HF containing 10% anisole for 1 h at 4°C. Peptides 
were then extracted with ether,  dissolved in  10%  aqueous  acetic  acid, 
filtered to remove the resin, and lyophilized. Peptides were checked for pu- 
rity by high pressure liquid chromatography, amino acid analysis, and amino 
acid sequencing. 
Peptides were HPLC purified at a semi-preparative scale using a 21.1  × 
250 mm C18 reverse phase column and a gradient of acetonitrile in water 
containing 0.1%  (vol/vol) of trifluoroacetic acid.  In the experiments, we 
originally used HPLC-purified peptides and eventually nonHPLC-purified 
batches in the cases where the biological activity was tested and found to 
be similar to the HPLC-purified material. 
Iodination of  Laminin and Peptides 
I_ztminin  and peptides (either as shown in Table I or with an addition of one 
tyrosine at their carboxy terminus) were iodinated by using the chloramine 
T method (12). Laminin was iodinated using chloramine T at a concentra- 
tion 1,000 times lower than originally described. After iodination, laminin 
was purified by gel filtration on a 1 x  25 cm Sephadex G-25 column (Phar- 
macia Fine Chemicals, Piscataway,  NJ) and subsequently dialyzed against 
Dulbecco's  PBS.  Iodinated  peptides  were  purified  on  SEP-PAK  C-18 
columns (Waters Associates, Milford, MA) and eluted with 50%  acetoni- 
trile in water containing 0.1% (vol/vol) trifluoroacetic acid. Eluted peptides 
were lyophilized and stored at  -70°C. 
Modification of  Peptide  F-9 
The free amino groups of peptide F-9 were modified with acetic anhydride 
(2). 5 mg of peptide F-9 was dissolved in 0.5 ml DMSO, then 1.5 ml of PBS, 
pH 7.4, was added. Acetic anhydride at a molar ratio to peptide of 1.5:1 was 
added slowly with stirring on ice. The reaction was allowed to proceed for 
30 min at 4°C, while the pH was adjusted to 7.0 with 0.1  M NaOH. After 
the reaction, the modified peptide was separated from the other reagents on 
a  1  x  25  cm column of Sephadex G-IO  (Pharmacia  Fine Chemicals) 
equilibrated with 25 mM NH4HCO3, pH 7.8. Fractions were monitored for 
peptide content spectrophotometrically at OD28o. The eluted protein peaks 
were lyophilized and stored at -70°C. The total yield was 60% of the start- 
ing material. 
The extent of modification which occurred at the free e-amino group of 
the lysine residue was quantitated by use of the enzyme endoproteinase 
Lys-C (Boehringer-Mannheim Diagnostics, Inc., Indianapolis, IN).  This 
enzyme cleaves specifically at the carboxy group of any intact lysine; how- 
ever, when the side chain of the lysine is modified, this cleavage does not 
take place (37). Control and modified peptide F-9 were incubated for 1 h, 
at 37°C,  at an enzyme to substrate ratio of 1:100. Samples were also in- 
cubated in the absence of enzyme. At the end of the incubation, an HPLC 
profile of the modified peptide was compared to the profile of the control 
peptide and the reduction of the peptide peak was used as a way to quantitate 
the enzymatic cleavage. 
Ce//s 
The ceils used in this study included: uv-2237-MM  murine fibrosarcoma 
and K-1735-M4  mnrine melanoma,  kindly provided by  Dr.  I.  J.  Fidler 
(M. D.  Anderson Hospital,  University of Texas  Health Science Center, 
Houston, TX); bovine aortic endothelial ceils isolated from bovine calf tho- 
racic aortas by collagenase digestion were provided by T. Herbst (University 
of Minnesota, Minneapolis, MN) as described (32);  C6 rat glioma cells 
from the American Type Culture Collection (Rockville, MD) (CCL 107); 
and PC12 rat pheochromocytoma was kindly provided by Dr. Lloyd Green 
(New York Universiity, NY). All of the cell lines except the pheochromocy- 
toma cells were maintained in DME (Gibco Laboratories, Grand Island, 
NY) containing 10% fetal bovine serum (FBS), at 37°C in a humidified in- 
cubator containing 5% CO2.  In the case of the pheochromocytoma cells, 
the media used was DME containing 10%  FBS and 5% horse sera. 
Direct Solid-Phase-binding Assays 
The binding of [3H]beparin to the various  peptides was measured by direct- 
binding assays using two different solid supports, nitrocellulose filters and 
polystyrene plates. For the nitrocellulose dot blot assays, stock solutions of 
peptides were made at a concentration of 1 mg/ml in 50 mM ammonium 
bicarbonate, pH 7.8, and serially diluted 1:1 in the same buffer,  producing 
final concentrations ranging from 1 mg/ml to 1 v.g/ml. 100/al of each con- 
centration was blotted onto a  nitrocellulose filter under suction, using a 
Minifold Microsample Filtration Manifold (Schleicher & Schuell, Keene, 
NH). Each well was then rinsed with 200 I.tl of the same buffer three times. 
The filter was dried overnight at 22°C, then incubated for 2 h with 50,000 
dpm/ml of [3H]heparin (0.3 mCi/mg; New England Nuclear,  Boston, MA). 
The filter was then washed four times, 5 min each, with I0 mM Tris-HCI, 
pH 8.0. Areas where peptides were blotted were then cut out, immersed in 
Ecolite scintillation fluid (WestChem, San Diego, CA), and counted in a 
Beckman LS-3801  scintillation counter. 
Direct solid-phase-binding assays were also performed in 96-well poly- 
styrene Immulon 1 plates (Dynatech Laboratories, Inc., Alexandria, VA) as 
previously described (34). Stock solutions of peptides at a maximum con- 
centration of 1 mg/ml were prepared in PBS containing 0.02%  NAN3; pep- 
tides were then serially diluted 1:1 in the same buffer, producing final con- 
centrations ranging from 1 mg/ml to 2 I.tg/ml. 50 I.tl of each concentration 
was added to the wells and dried overnight at 29°C. Wells were then treated 
for 2 h at 37°C with 200 al of 2 mg/ml BSA (Fatty Acid Free, fraction V, 
ICN Immunobiologicals, Lisle, IL), in 6 mM phosphate, 100 mM NaCI, 
60  gM  CaCI2,  pH  6.8  (wash buffer) to  minimize nonspecific binding. 
Next, 50 ~1 of [3H]heparin  (10  v.g/ml  in the same buffer) was added to 
each well (50,000 dpm/well) and incubated for 2 h at 37°C. The wells were 
rinsed three times with wash buffer containing 0.1%  3-[(3-cholamidopro- 
pyl)dimethyl-ammonio]l-l-propanesulfonate  and then incubated for 30 rain 
at 60°C with 200 I.tl of 0.5 N NaOH and 1% SDS. The amount of [3H]hep- 
arin bound was quantitated as described above. 
Inhibition-binding Assays 
Inhibition-binding assays were performed by two different techniques: in the 
frst, laminin was immobilized on plastic; in the second, heparin was im- 
mobilized on beads. 
In the first assay,  laminin at 60 gg/ml in PBS containing 0.02%  NaN3 
was coated onto 96-well polystyrene plates, using 50 gl per well and dried 
overnight at 29°C. The wells were then blocked for 2 h at 37°C with 2 mg/ml 
BSA in wash buffer.  Peptides at various dilutions ranging from 0.5 mg/ml 
to  1 lag/ml in PBS containing 0.1%  3-[(3-cholamidopropyl)dimethyl-am- 
monio]-l-propanesulfonate were incubated concomitantly with [3H]beparin 
(25,000 dpm/well; 5 I.tg/ml final concentration) for 2 h at 37°C in polypro- 
pylene tubes. 50  p,L of the mixture was then transferred to the laminin- 
coated wells and allowed to incubate for an additional 2 h at 37°C. The wells 
were then rinsed with wash buffer containing 0.05 % Triton X-100 and the 
[3H]heparin  which bound was detected as described above. 
In the second assay, heparin-Sepharose beads (Pharmacia Fine Chemi- 
cals) were equilibrated in 6 mM phosphate, 100 mM NaCI, 60 I.tM CaCI:, 
pH 6.8. 0.5-ml aliquots of beads (packed beads:buffer at 1:1 volume ratio) 
were incubated in polypropylene tubes at 37°C for 1 h with each peptide 
at a final concentration of I mg/ml. To each tube, 20 gl of radiolabeled lami- 
nin (1 gg/ml; 50,000  dpm/20 gl) was added for another hour at 37°C.  At 
the end of this incubation period, the beads were transferred to small col- 
umns, rinsed with 10 ml of buffer (flow rate 2 ml/min), air dried, and placed 
in the gamma counter to measure the radioactivity left on the column. 
Nonspecific binding was measured as the amount of ~2~I-laminin which 
bound to plain Sepharose beads. In these experiments, 13.9%  of the total 
laminin counts were found to adhere nonspecifically. 
Specificity of  Peptide  F-9 Binding to Heparin 
To determine the importance of the heparin structure for this interaction, 
3.0 gg per well of peptide F-9 was dried onto 96-well plates as described 
above. Wells were blocked for 2 h with 2 mg/ml BSA in wash buffer.  To 
each well, 50 gl of [3H]heparin  (50,000  @m/well) was added concomi- 
tantly with various amounts of unlabeled heparin, dextran sulfate, and der- 
matan sulfate.  After incubating for 2 h at 37°C, the wells were washed and 
the radioactivity was detected as described above. 
To determine the importance of the free amino groups of peptide F-9 in 
its interaction with heparin, we modified peptide F-9 as described above, 
and then used it in the first type of inhibition assay (laminin-coated plates) 
exactly as described above. 
Cell Adhesion Assays: Direct Binding 
Five different cell types were tested for their ability to adhere to substrates 
coated with laminin and the synthetic peptides in assays similar to those pre- 
viously described (27). Briefly,  mid to late log phase cells were incubated 
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Peptide  Amino acid sequence* 
Hydropathy  Number of lysines 









641-660  -3.9  4 
960-978  -20.7  3 
1,133-1,148  -14.8  3 
1,171-1,188  --12.9  5 
* Sasaki et al.  (see reference 31). 
overnight in DME containing 10% FBS plus either 3 pCi/ml of [JH]thymi- 
dine (6.7 Ci/mmol, New England Nuclear, Boston, MA) for the fibrosar- 
coma and melanoma cell lines, or 30 IxCi/ml of 3H-L-amino  acid mixture 
(240  mCi/ml,  ICN  Radiochemicals,  Irvine,  CA)  for  the  glioma  and 
pheochromocytoma cell lines and the endothelial cells. The cells were har- 
vested by gentle trypsinization (two l-rain rinses with 0.05 % trypsin and 0.5 
mM ethylenediaminetetraacetic acid) and the trypsinization was terminated 
by the addition of DME containing 10% FBS. Removal of pheochromocy- 
toma cells from the flasks was achieved by incubating cells for 10 rain in 
Hanks' balanced salt solution (HBSS)  without CaCI2 or MgSO4  (Sigma 
Chemical Co.), instead of trypsin. All cells were washed with DME con- 
raining 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic  acid (Sig- 
ma Chemical Co.), pH 7.4,  resuspended to 4  x  104 cells/ml in the same 
buffer containing 2 mg/ml BSA.  100 Ixl of the cell suspension was placed 
in wells of polystyrene plates which had been precoated with L0 p,g of the 
peptides, laminin, or BSA. The cells were incubated in the wells for 2 h 
at 37°C, then nonadherent cells were aspirated off and the wells were rinsed 
three times with 2 mg/ml BSA in DME containing 20 mM N-2-hydroxy- 
ethylpiperazine-N'-2-ethanesulfonic acid.  Adherent cells were solubilized 
with 200 p.1 of 0.5 N NaOH and 1% SDS, and quantitated in a scintillation 
counter. 
Cell Adhesion Assays: Competition of  Binding 
The competition assays concentrated on only the melanoma cell line. They 
were grown, labeled, and harvested as described above. For 30 min before 
transfer to laminin-coated 96-well plates (coated as described above) and 
during a 20-min incubation, various potential inhibitors of cell adhesion 
were present in solution. These included: laminin or peptides F-9,  F-11, 
F-12,  or F-13 at a final  concentration of 150 pg/ml. Control experiments 
were done in the absence of inhibitors. Cells were photographed 20 rain af- 
ter they had been transferred to the laminin-coated wells, at a final magnifi- 
cation of 400x  with a  Nikon DIAPHOT inverted microscope and Pana- 
tomic X Film ASA32 (Eastman Kodak, Rochester, NY). All experiments 
described were performed in triplicate and repeated a  minimum of two 
times. 
Results 
Data obtained by our group in the past using well character- 
ized monoclonal antibodies (33, 34) and direct observations 
with the technique of rotary shadowing (not shown) strongly 
suggested that a heparin-binding site on laminin might exist 
in the area between the inner globule of the lateral short arms 
and the cross region. To more precisely map this heparin- 
binding domain, we selected a variety of regions from the 
published amino acid sequence of the B1 chain of laminin, 
based on two criteria: First, the region was required to have 
a relatively low (negative) value of hydropathy index (16), 
based upon the finding that the heparin-binding domain of 
vitronectin was localized in a region with the most negative 
hydropathy index  (36).  To  apply  this  criterion,  we  con- 
structed the hydropathy index of the full sequence of the B1 
chain, using the Intelligenetics (Mountain View, CA) com- 
puter program with a span setting of 7 amino acids (data not 
shown). Second, since electrostatic forces may play a major 
role in the interactions between proteins and heparin,  the 
regions selected had a relatively high number of the strongly 
positively charged amino acid residues lysine and arginine. 
The amino acid sequences of the peptides which were syn- 
thesized and used in this study and their localization along 
the B1 chain are shown in Table I and Fig. 1. Other character- 
istics of each peptide, including the hydropathy value and the 
number of arginine and lysine residues present are also listed 
in Table I. 
Binding of rH]Heparin to Synthetic Peptides 
The direct binding  of [3H]heparin  to  peptides  which had 
been dried onto nitrocellulose filters was determined (Fig. 
2).  The actual  amount of each peptide that was retained  on 
the filter was quantitated by using iodinated peptides, as de- 
scribed in the Materials and Methods.  Peptide F-9 was the 
only peptide to which [3H]heparin  bound.  Similar experi- 
ments using polystyrene plates as a surface to which peptides 
were dried gave similar results  (not shown). 
Since these assays  were performed with the peptides im- 
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Figure 1. Diagrammatic model of the B1 chain of laminin indicating 
the location of the synthesized peptides. The B1  chain of laminin 
is drawn according to Sasaki et al. (31) and indicates the approproxi- 
mate location of peptides F-9, F-II, 1=-12, and F-13 which were syn- 
thesized and used in this study. 
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Figure 2.  Binding  of heparin  to  laminin  peptides  dried  onto 
nitrocellulose.  100 ttl of  peptide solutions at various concentrations 
(starting from 500 pg/ml) were blotted on nitrocellulose. Then, the 
filter was incubated with pH]heparin for 2 h, as described  in Ma- 
terials and Methods. The actual amount of peptide retained on the 
filter was calculated in experiments using iodinated peptides with 
SEM <  5%. 1=-9 (o), F-II (m), F-12 (~), and F-13 (n). 
mobilized on a  solid matrix,  we were concerned that im- 
mobilization might affect the biological or functional proper- 
ties  of the  peptides.  Therefore,  an  inhibition  assay  was 
designed  in  which  the  binding  of [3H]heparin  to  laminin 
coated on plastic was monitored in the presence of peptides 
in solution.  Only peptide F-9 was able to inhibit [3H]hepa- 
rin binding to laminin (Fig. 3); confirming the results of the 
direct-binding assays. This inhibition could be observed at 
concentrations as low as 10 ttg/ml and reached 50% inhibi- 
tion  at  60  rtg/ml.  As  a  control,  the  *25I-labeled peptides 
were added to wells coated with laminin; no binding between 
laminin  and  any  of the  peptides  was  observed  (data  not 
shown). This finding ruled out the possibility that inhibition 
of heparin-laminin interaction was due to masking of hepa- 
rin-binding sites on laminin by the peptides. 
Since laminin was adsorbed onto plastic in these inhibition 
Figure 4.  Inhibition  of laminin-heparin  interaction  by synthetic 
peptides.  Heparin-Sepharose beads  were incubated for 1 h with 
various peptides at a final concentration of 1 mg/ml. Then, a small 
amount of radioactive laminin was added and the mixture was fur- 
ther incubated for another hour. At the end of the final incubation, 
beads were washed and counted,  with SEM <  5%. 
assays, it is possible that it was not present in its native state. 
Therefore, another assay was conducted to further examine 
the interaction of heparin with peptide F-9 and laminin in an 
experimental  system where  both  laminin and  peptide  F-9 
would be in solution. Heparin-Sepharose beads were pre-in- 
cubated with various peptides at 1 mg/ml, a standard amount 
of radiolabeled laminin was then added, and the amount of 
laminin bound was quantitated as described under Materials 
and Methods.  As expected, peptide F-9 was the only pep- 
tide which competed for the binding of laminin to heparin 
(Fig. 4). 
The  three  different  experimental  approaches  described 
above indicate that peptide F-9 binds to heparin under condi- 
tions in which both molecules are in solution or either one 
of them is immobilized on a  solid support. 
Specificity of  the Interaction Between 
Peptide F-  9 and Heparin 
To  understand  the  structural  features  of peptide  F-9  and 
heparin that are crucial for their interaction, structurally al- 
tered molecules were then tested for functional activity. 
Heparin is composed of a  number of negatively charged 
groups,  in  particular,  sulfate  groups.  Two  other  sulfated 
,• 
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Figure 3, Inhibition  of the binding of hcparin to ]aminin by synthetic 
peptides. Peptides at various concentrations were incubated with 
pH]heparin  for  2  h  and  then  the  mixture  was  transferred  to 
laminin-coated polystyrene wells for 2 h as described in Materials 
and Methods,  with SEM < 5%. F-9 (e), F-II (m), F-12 (z~), F-13 
(c3), and modified (acetylated)  F-9 (<3). 
¢o~amt~n o~ tr,  tat~r (M| 
Figure 5.  Competition  of [3H]heparin-binding to peptide  F-9 by 
sulfated polysaccharides.  Wells coated  with  3 ~tg of peptide  F-9 
were  incubated for 2 h with  [3H]heparin and various concentra- 
tions of unlabeled heparin  (c3), dextran sulfate (,) and dermatan 
sulfate (4), with SEM < 5 %. 
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Laminin- and F-  9-coated Dishes 
Cells adhered 
Cell line  Laminin*  F-9t 
%  % 
Murine melanoma (M4)  28  30 
Murine fibrosarcoma (MM)  52  64 
Rat pheochromocytoma (PCI2)  34  60 
Rat glioma (C6)  50  59 
Bovine aortic endothelial cells (BAEC)  18  23 
* Final amount retained on the well: 700 ng. 
Final amount retained on the well:  69 ng. 
polysaccharides with a different structure of the repeated di- 
saccharide unit, dermatan sulfate and dextran sulfate, were 
tested  with heparin in competition-binding experiments. In 
this assay, peptide F-9 was dried onto polystyrene plates at 
3 lxg/well. Under these conditions, 150 ng of peptide F-9 is 
adsorbed and retained on the plastic well. The direct binding 
of a standard amount of [3H]heparin  to the coated peptide 
was competed off by various concentrations of unlabeled 
heparin, dermatan sulfate, and dextran sulfate (Fig. 5).  A 
50% inhibition of binding of [3H]heparin was achieved with 
'~,9  x  10  -s M unlabeled heparin, while seven times more 
dextran sulfate (6  ×  10  -7 M) or 110 times more dermatan 
sulfate (1  ×  10  -s M) was required for similar levels of in- 
hibition. These results  suggest that although the negative 
charges of the polysaccharides might play an important role 
in mediating the binding, other structural features of heparin 
might have a crucial contribution as well. 
Peptide F-9 was then chemically modified to determine 
whether free amino groups are important for heparin-bind- 
ing activity. This peptide contains two free amino groups: an 
a-amino group present on the first arginine residue and an 
e-amino group present on the lysine residue. In situ in the 
B1 chain, only the e-amino group of lysine is present because 
the a-amino group of arginine is involved in the formation 
of a peptide bond. The importance of the free amino groups 
in heparin-binding was determined by modification with ace- 
tic anhydride, a chemical which reacts specifically with free 
amino groups (2, 37). 
After treatment with acetic anhydride, the extent of modi- 
fication of the ~-amino group of lysine was assessed by treat- 
ment with endoproteinase Lys-C. This enzyme cleaves at the 
carboxy terminal of intact lysine residues but fails to do so 
when the ~-amino group is modified (37).  Both intact and 
modified peptide  F-9  were  digested  as  described  under 
Materials and Methods, and the disappearance of the peptide 
peak on the HPLC profile was measured. In the case of the 
intact peptide,  the peak totally disappeared  after 60  rain 
digestion. Under identical conditions, the modified peptide 
peak was reduced only by 27 %. We concluded that over 70% 
of the ~-amino groups  of lysines have been  successfully 
modified. 
The ability of modified peptide F-9 to bind heparin in solu- 
tion  was  measured  using  laminin dried  onto plastic.  As 
shown in Fig. 3, modified peptide F-9 was no longer able to 
compete for the binding of heparin to laminin. These results 
suggest that the free amino groups ofpeptide F-9 and/or their 
Table III. Inhibiffon of  Melanoma Cell Adhesion on 
Laminin-coated  Wells by Various lnhibitors in Solution 
Inhibition of melanoma 
Competitor*  cell adhesion 
% 
None  0 
Laminin  63 
F-9  49 
F-II  0 
F-12  5 
F-13  9 
* Final concentration: 150 gg/ml. 
environment may be crucial areas for the heparin-binding 
property of this laminin fragment. 
Effect of  Peptide F-9 on Cell Adhesion 
Because many cells may exhibit heparin-like structures on 
their surfaces (8, 20, 25, 35), we investigated the role of our 
synthetic peptides in the phenomenon of cell adhesion. The 
results described so far made us put specific emphasis on the 
activity of peptide F-9. 
In the first series of experiments, polystyrene plates were 
coated with either laminin or peptide F-9. The total amount 
of each protein dried down was 1 ~g. Under these conditions 
700 ng of laminin and 69 ng of peptide F-9 remain attached 
to the solid support during the course of the experiment, as 
calculated  by using radiolabeled  proteins.  After  coating  and 
blocking the  plates,  radiolabeled  cells  were incubated in the 
wells for 2 h, as described in Materials and Methods. The 
number of  cells  that  adhered in  each well  was quantitated  as 
a  percentage of  cell  adhesion and was calculated  by compar- 
ing the radioactivity  remaining in the well  at  the end of the 
experiment with the  total  radioactivity  added to  the  well.  The 
results  shown in Table II indicate  that  peptidc F-9 promotes 
the  adhesion of  all  of  the cell  lines  examined at  a level  com- 
parable  to intact  laminin. Despite the fact  that  under our ex- 
perimental conditions the molarity of  the peptide is higher 
than that  of  laminin, it  is still  remarkable that  such a small 
fragment oflaminin 0ess than 1/300th  of  its  molecular mass) 
is  so  potent  in  promoting cell  adhesion. Under the same ex- 
perimental conditions, the other peptides and BSA did not 
promote or only slightly  promoted cell  adhesion (data  not 
shown). 
We then concentrated on one particular cell line, the mela- 
noma cells, to further study cell adhesion. In this series of 
experiments, melanoma cells  were preincubated with lami- 
nin  or  one  of  the  peptides,  then  added to  laminin-coated  wells 
in the presence of these potential inhibitors.  The results 
shown in Table HI demonstrate that  laminin was able  to in- 
hibit  melanoma cell  adhesion by 63%, peptide F-9 created 
a  49  % inhibition,  whereas the  other  peptides  did  not  produce 
any substantial  inhibition.  These results  suggest  that  peptide 
F-9 is  capable of  regulating  cell  adhesion not only while ad. 
sorbed on plastic,  but also when present in solution. 
The effect  of  peptide  F-9 on the  morphology of  melanoma 
cells  during adhesion was examined with  a  photomicroscope 
during the  course of  the  previously  described experiment. As 
seen in Fig. 6, cells  incubated with peptide F-9 in solution 
were mostly rounded and only a few of them appeared at- 
Charonis et al. Laminin Peptide Causing Heparin and Cell Binding  1257 Figure 6. Inhibition of cell adhesion by peptide F-9 in solution. Melanoma cells were harvested with light trypsinization, washed, and 
incubated for 30 min in 150 Itg/ml of inhibitors (laminin or the various peptides). The cell suspensions were then placed in laminin-coated 
polystyrene wells at a density of 4  ×  104 cells/ml, and photographed after 20 min. A is in the absence of inhibitor. The same cell mor- 
phology was observed in the presence of peptides F-11, F-12, and F-13. B is in the presence of peptide F-9. The same cell morphology 
was observed in the presence of laminin. 
tached to the laminin-coated substrate (Fig. 6 B), whereas 
absence of peptide F-9 allowed the vast majority of cells to 
be well attached to the substrate (Fig.  6 A). This microscopic 
observation confirms our previous finding and further sug- 
gests a role of peptide F-9 in melanoma cell adhesion. 
Discussion 
In this study,  a synthetic peptide 20 amino acids long from 
the B1 chain of laminin has been shown to exhibit heparin- 
binding activity and to promote the adhesion of various cell 
lines. 
Our previous work has demonstrated that, apart from the 
heparin-binding domain on the globule of the long arm origi- 
nally described by Ott et al. (26), other heparin-binding do- 
mains exist on the laminin molecule (34). One of them was 
suggested to be localized to the lateral short arm between the 
inner globule and the cross region (34). Rotary-shadowing 
observations also supported this finding, by demonstrating a 
high frequency of heparin binding at or near the inner glob- 
ule of the lateral short arm (unpublished observations). Ac- 
cording to the model of the B1 chain structure by Sasaki et 
al. (31), peptide F-9 belongs to the amino acid sequences that 
form the inner globule of the lateral  short arm  of the BI 
chain. 
The data in this report suggest that the binding of heparin 
to peptide F-9 is specific and is not due exclusively to ionic 
interactions, since other peptides with higher charge densi- 
ties fail to bind heparin. The factors that determine whether 
an amino acid sequence will bind to heparin are not fully 
known.  Our  findings  indicate that  neither a  very low hy- 
dropathy  value  nor  a  high  density  of positively charged 
amino acid residues are absolute prerequisites. The peptides 
synthesized in this study fulfilled both of these criteria, yet 
only one of them exhibited binding to heparin. Perhaps the 
exact conformation of each peptide is the crucial factor. The 
distance that charged amino acid residues are spaced apart 
may also be an important parameter. Additionally, the struc- 
tural conformation of the glycosaminoglycan chain might be 
crucial. The type and amount of  hexosamine and uronic acid, 
the type of bond they form with each other or with the next 
dissaccharide unit (1--'3 or 1-'4), and the degree of sulfation 
could all be determining factors in their binding to specific 
amino acid sequences. These factors could actually confer 
some specificity in the binding of each type of glycosamino- 
glycan to different polypeptides. 
The finding that modification of the free amino groups of 
peptide F-9 affects heparin binding suggests that at least two 
residues (the first arginine and the lysine) and/or their envi- 
ronment might be crucial for this interaction. Further work 
is in progress in order to understand the minimal structural 
requirements for the heparin-binding and cell-binding activi- 
ties of peptide F-9. 
In these studies, heparin was used as a prototype for a pro- 
teoglycan molecule. Although free heparin may not exist as 
a bona fide basement membrane component, many heparin- 
like  domains  are  present  in  the  environment of laminin. 
These include glycosaminoglycan side chains of basement 
membrane proteoglycans (7,  13,  15,  18, 35) and of cell sur- 
face associated proteoglycans of various cell types associated 
with basement membranes (8, 20,  35). It has recently been 
reported that an endothelial cell-derived heparan sulfate pro- 
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gions of its side chains (25). Therefore, the heparin-binding 
sites on laminin may be crucial not only for the structural ar- 
rangement of basement membrane components but also for 
regulating cell adhesion to laminin. 
Laminin may contain multiple cell adhesion promoting 
domains and some of them may be cell-type specific. Ter- 
ranova et al. have proposed that a cell-binding site for human 
breast carcinoma cells exists on a chymotrypsin fragment of 
laminin that was thought to consist of the inner nonglobular 
regions of the three short arms (38). Timpl et al. have sug- 
gested that proteolytically derived fragments P1, E5, and E6 
represent three distinct laminin domains that promote hepa- 
tocyte adhesion (40). The P1 fragment is thought to contain 
the nonglobular regions of the three short arms next to the 
cross. Fragments E5 and E6 are possibly derived from the 
globules of  the short arm opposite to the long arm of laminin. 
Goodman et al. have recently provided evidence that human 
glioblastoma cells adhere to laminin via two different bind- 
ing sites, one site located on fragment E  1-4 which consists 
of the three short arms, and another site located on fragment 
E8 which consists of the major part of the long arm, includ- 
ing its terminal globule (9). We have observed that a domain 
in the upper third of the long arm of laminin might be impor- 
tant in mediating the adhesion of murine melanoma cells 
(33). 
It would be of interest to more precisely localize the cell 
adhesion  domains  of laminin  to  specific  amino  acid  se- 
quences. Recently, the full sequence of the B1 chain of lami- 
nin was published (31). Graf et al. have provided evidence 
that the nonapeptide CDPGYIGSR from the B1 chain pro- 
motes the attachment of HT-1080 human fibrosaroma cells 
and Chinese hamster ovary cells (10). In this report, we pro- 
vide the sequence of an additional domain from the B1 chain 
of laminin that promotes the adhesion of murine melanoma, 
murine fibrosarcoma, rat glioma,  rat pheochromocytoma, 
and bovine aortic endothelial cells. Peptide F-9 has the abil- 
ity to bind to heparin and to promote the adhesion of various 
cell lines. These findings suggest that cell surface-associated 
heparin-like molecules may act as receptors for these lami- 
nin domains. However, it cannot be ruled out that domains 
from the  CSAT/integrin  complex  (11), other  macromole- 
cules, or sulfated glycolipids (29) might participate in the 
binding to this laminin domain. 
Peptide F-9 contains the sequence Asn-Tyr-Thr which is a 
possible acceptor site of N-linked oligosaccharide moieties 
close to its carboxyl terminal. It is not yet known whether 
and to what extent laminin is glycosylated in this region and 
to  what  extent  this  post-translational  modification  could 
affect the heparin-binding properties of this fragment. If this 
is  the  case,  differential glycosylation patterns  leading  to 
different functional properties of the laminin molecule could 
be possible. 
This novel heparin-binding and cell adhesion-promoting 
region is localized on the inner globule of the lateral short 
arm of laminin formed by the B1 chain. This site is relatively 
close to the cell-binding site described by Graf et al. (10) and 
possibly close to two other important binding sites on the 
lateral short arms of laminin for entactin/nidogen (24, 28) 
and for type IV collagen (38) (if either one or both of them 
are localized on the B1 chain). Such close arrangement of in- 
teractive sites for basement membrane macromolecules and 
cell surfaces might be crucial for the structural diversity of 
basement membranes (3). 
It has been suggested that during development (5) and in 
certain tissues (14) there are different levels of mRNAs cod- 
ing for the three laminin chains. If the levels ofmRNA reflect 
the actual amount of each chain present in the tissue and are 
not due to differential message turnover, then the possibility 
exists that different forms of laminin could be present. In the 
kidney, the message for the B1 chain has been detected in 13- 
fold excess of the message for the A chain (15).  If laminin 
is mainly present in this tissue in a form partially or totally 
lacking the A-chain, then the heparin-binding domain local- 
ized on the globule of the long arm will be absent. In this 
case, the newly described heparin-binding domain on the B1 
chain of laminin could play a major role in the organization 
of kidney basement membranes. 
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